19 April 2018
Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282, was presented at the 2018 International Liver Congress (ILC) in Paris, France.
18 April 2018
A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of anti-PD-1 and –PD-L1 checkpoint inhibitors (CPIs) in the clinic.
17 April 2018
ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
Evidence that Allergan’s Phase III drug candidate, cenicriviroc, may benefit non-alcoholic steatohepatitis (NASH) patients was presented at the 2018 International Liver Congress (ILC) in Paris, France.
3 April 2018
Dutch company Escalier Biosciences has raised funds of $19M to develop psoriasis treatments. The funding will be utilised to develop systemic and oral treatments for psoriasis and other autoimmune diseases,...
21 March 2018
Disability caused by brain tissue damage as a result of acute ischemic stroke (AIS) often requires extended hospitalisation and rehabilitation, representing a significant socioeconomic burden. A major focus of AIS...
20 March 2018
Developers have historically faced difficulties in finding effective agents to treat patients with glioblastoma multiforme (GBM), the most common form of grade IV brain cancer.
19 March 2018
During an analysis of all clinical trials with a start date in 2017, GlobalData analysts found that pain was the most frequent indication across the period, with 9% of total...
14 March 2018
GlobalData has reviewed the status of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. Over the 10-year period, 41% of trials were recruiting;...
13 March 2018
GlobalData analysed the number of clinical trials examining the microbiome with start dates between 1 January 2012 and 31 December 2017.
12 March 2018
Involving patients in clinical trials is often quite challenging, and this challenge becomes more difficult when dealing with the recruitment of patients for rare diseases. At the Orphan Drugs &...